7 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisDigestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitisRecruitingPhase 32026-10-06NCT06051617
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitisActive, not recruitingPhase 32026-09-01NCT04526665
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated RegimenHIV-1-infectionActive, not recruitingPhase 2 / Phase 32026-08-10NCT05502341
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With BiktarvyHIV-1-infectionActive, not recruitingPhase 32026-06-15NCT06333808
A Longitudinal Observational Study of the Natural History and Management of Patients With HCCDigestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Site, liver disorder, neoplasmActive, not recruitingNot stated2026-04-17NCT02954094
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Subcutaneous Emphysema, alpha 1-antitrypsin deficiency, hereditary disease, liver disorder, lung disorder, pulmonary emphysema, respiratory system disorderRecruitingPhase 32026-03-05NCT06165341
Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIVHIV-1 InfectionActive, not recruitingPhase 22026-02-04NCT05052996